3.Pawson T, J Guyden, T-H Kung, K Radke, T Gilmore & GS Martin. 1980. A strain of Fujinami sarcoma virus which is temperature-sensitive in protein phosphorylation and cellular transformation. Cell 22: 767-775. (Abstract Link)

4.Gilmore T, K Radke & GS Martin. 1982. Tyrosine phosphorylation of a 50K cellular polypeptide associated with the Rous sarcoma virus transforming protein, pp60src. Molecular and Cellular Biology 2: 199-206. (Abstract Link)

5.Gilmore T & GS Martin. 1983. Phorbol ester and diacylglycerol induce protein phosphorylation at tyrosine. Nature 306: 487-490. (Abstract Link)

6.Martin GS, K Radke, C Carter, P Moss, P Dehazya & T Gilmore. 1984. The role of protein phosphorylation at tyrosine in transformation and mitogenesis. Cold Spring Harbor Conference on Cell Proliferation and Cancer. Journal of Cell Physiology Supplement 3: 139-149. (Abstract Link)

7.Moss P, K Radke, V Carter, J Young, T Gilmore & GS Martin. 1984. Cellular localization of the transforming protein of wild-type and temperature-sensitive Fujinami sarcoma virus. Journal of Virology 52: 557-565. (Abstract Link)

8.Gilmore T, J DeClue & GS Martin. 1985. Tyrosine kinase activity associated with the v-erbB gene product.  In, The Cancer Cell (eds. G Ferramisco, B Ozanne, and C Stiles) Volume 3: 25-32.

9.Gilmore TD, J DeClue & GS Martin. 1985. Protein phosphorylation at tyrosine is induced by the v-erbB gene product in vivo and in vitro. Cell 40: 609-618. (Abstract Link)

10.Gilmore TD & HM Temin. 1986. Different localization of the product of the v-rel oncogene in chicken fibroblasts and spleen cells correlates with transformation by REV-T. Cell 44: 791-800. (Abstract Link)

11.Luk K-C, T Gilmore & A Panganiban. 1987. The spleen necrosis virus int gene product expressed in Escherichia coli has DNA binding activity and mediates att and U5-specific multimer formation in vitro. Virology 57: 127-136. (Abstract Link)

12.Gilmore TD & HM Temin. 1988. v-rel oncoproteins in the nucleus and in the cytoplasm transform chicken spleen cells. Journal of Virology 62: 703-714. (Abstract Link)

13.Capobianco A, DL Simmons & TD Gilmore. 1990. Cloning and expression of a chicken c-rel cDNA:  unlike p59v-rel, p68c-rel is a cytoplasmic protein in chicken embryo fibroblasts. Oncogene 5: 257-266. (Abstract Link)

14.Delwart EL, G Mosialos & T Gilmore. 1990. Retroviral envelope glycoproteins contain a “leucine zipper”-like repeat. AIDS Research and Human Retroviruses 6: 703-706. (Abstract Link)

15.Kamens J, P Richardson, G Mosialos, R Brent & TD Gilmore. 1990. Oncogenic transformation by vRel requires an amino-terminal activation domain. Molecular and Cellular Biology 10: 2840-2847. (Abstract Link)

16.Gilmore TD. 1990. NF-kB, KBF1, dorsal, and related matters. Cell 62: 841-843. (Abstract Link)

17.Dailey D, GL Schieven, MY Lim, T Gilmore, J Thorner & GS Martin. 1990. Novel yeast protein kinase (YPK1 gene product) is a 40-kilodalton phosphotyrosyl protein associated with protein-tyrosine kinase activity. Molecular and Cellular Biology 10: 6244-6256. (Abstract Link)

18.Richardson PM & TD Gilmore. 1991. vRel is an inactive member of the Rel family of transcriptional activating proteins. Journal of Virology 65: 3122-3130. (Abstract Link)

19.Gilmore TD. 1991. Malignant transformation by mutant Rel proteins. Trends in Genetics 7: 318-322. (Abstract Link)

20.Mosialos G, P Hamer, AJ Capobianco, R Laursen & TD Gilmore. 1991. A protein kinase A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel. Molecular and Cellular Biology 11: 5867-5877. (Abstract Link)

21.Capobianco A & TD Gilmore. 1991. Repression of the chicken c-rel promoter by vRel in chicken embryo fibroblasts is not mediated through a consensus NF-kB binding site. Oncogene 6: 2203-2210. (Abstract Link)

22.Morin P & TD Gilmore. 1992. The C terminus of the NF-kB p50 precursor protein and an IkB isoform contain transcription activation domains. Nucleic Acids Research 20: 2453-2458. (Abstract Link)

23.Capobianco AJ, D Chang, G Mosialos & TD Gilmore. 1992. p105, the NF-kB p50 precursor, is one of the cellular proteins complexed with the v-Rel oncoprotein in transformed chicken cells. Journal of Virology 66: 3758-3767. (Abstract Link)

24.Gilmore TD. 1992. Role of rel family genes in normal and malignant lymphoid cell growth. Cancer Surveys 15: 69-87. (Abstract Link)

25.Morin PJ, G Subramanian & TD Gilmore. 1992. AAT1, a gene encoding a mitochondrial aspartate aminotransferase in Saccharomyces cerevisiae. Biochimica et Biophysica Acta 1171: 211-214. (Abstract Link)

26.Mosialos G & TD Gilmore. 1993. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence. Oncogene 8 :721-730. (Abstract Link)

27.Capobianco AJ & TD Gilmore. 1993. A conditional mutant of vRel containing sequences from the human estrogen receptor. Virology 193:1 60-170. (Abstract Link)

28.Morin PJ, GS Subramanian & TD Gilmore. 1993. GAL4-IkBa and GAL4-IkBg activate transcription by different mechanisms. Nucleic Acids Research 21: 2157-2163. (Abstract Link)

29.Sarkar S & TD Gilmore. 1993. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain. Oncogene 8: 2245-2252. (Abstract Link)

30.Sif S, AJ Capobianco & TD Gilmore. 1993. The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts. Oncogene 8: 2501-2509. (Abstract Link)

31.White DW & TD Gilmore. 1993. Temperature-sensitive transforming mutants of the v-rel oncogene. Journal of Virology 67: 6876-6881. (Abstract Link)

32.Sif S & TD Gilmore. 1993. NF-kB p100 is one of the high-molecular-weight proteins associated with the v-Rel oncoprotein in transformed chicken spleen cells. Journal of Virology 67: 7612-7617. (Abstract Link)

33.Gilmore TD & PJ Morin. 1993. The IkB proteins:  members of a multifunctional family. Trends in Genetics 9: 427-433. (Abstract Link)

34.Feinstein R, WK Bolton, JN Quinones, G Mosialos, S Sif, JL Huff, AJ Capobianco & TD Gilmore. 1994. Characterization of a chicken cDNA encoding the retinoblastoma gene product. Biochimica et Biophysica Acta 1218: 82-86. (Abstract Link)

35.Sif S & TD Gilmore. 1994. Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1. Journal of Virology 68: 7131-7138.  (Abstract Link)

36.White DW, A Roy & TD Gilmore. 1995. The v-Rel oncoprotein blocks apoptosis and proteolysis of IkB-a in transformed chicken spleen cells. Oncogene 10: 857-868. (Abstract Link)

37.Gilmore TD, DW White, S Sarkar & S Sif. 1995. Malignant transformation of cells by the v-Rel oncoprotein. In, The DNA Provirus:  Howard Temin’s Scientific Legacy (eds. GM Cooper, R Greenberg Temin, and B Sugden), American Society for Microbiology, Washington D.C., pp 109-128.

38.Morin PJ, J Downs, AM Snodgrass & TD Gilmore. 1995. Genetic analysis of growth inhibition by GAL4-IkB-a in Saccharomyces cerevisiae. Cell Growth & Differentiation 6: 789-798. (Abstract Link)

39.Gilmore TD. 1995. Regulation of Rel transcription complexes.  In, Frontiers in Molecular Biology: Eukaryotic Gene Transcription (ed. S Goodbourn), Oxford University Press, Oxford, England, pp 102-131.

40.White DW, GA Pitoc & TD Gilmore. 1996. Interaction of the v-Rel oncoprotein with NF-kB and IkB proteins:  heterodimers of a transformation-defective v-Rel mutant and NF-kB p52 are functional in vitro and in vivo. Molecular and Cellular Biology 16: 1169-1178. (Abstract Link)

41.White DW & TD Gilmore. 1996. Bcl-2 and CrmA have different effects on transformation, apoptosis, and the stability of IkB-a in chicken spleen cells transformed by temperature-sensitive v-Rel oncoproteins. Oncogene 13: 891-899. (Abstract Link)

42.Gilmore TD, M Koedood, KA Piffat & DW White. 1996. Rel/NF-kB/IkB proteins and cancer. Oncogene 13:1367-1378. (Abstract Link)

43.Gilmore TD (editor). 1997. Rel/NF-kB. Seminars in Cancer Biology, Academic Press, Cambridge, England. Volume 8-2, pp 61-129.

44.Barkett M, D Xue, HR Horvitz & TD Gilmore. 1997. Phosphorylation of IkB-a inhibits its cleavage by caspase CPP32 in vitro. Journal of Biological Chemistry 272: 29419-29422. (Abstract Link)

45.Gilmore TD. 1997. Clinically relevant findings. Journal of Clinical Investigation 100: 2935-2936. (Abstract Link)

46.Sylla B, SC Hung, DM Davidson, E Hatzivassiliou, NL Malinin, D Wallach, TD Gilmore, E Kieff & G Mosialos. 1998. Epstein-Barr virus transforming protein latent infection membrane protein 1 activates transcription factor NF-kB through a pathway that includes the NF-kB-inducing kinase and the IkB kinases IKKa and IKKb. Proceedings of the National Academy of Sciences USA 95: 10106-10111. (Abstract Link)

47.Wang Y, JE Dooher, M Koedood Zhao & TD Gilmore. 1999. Characterization of mouse Trip6: a putative intracellular signaling protein. Gene 234: 403-409. (Abstract Link)

48.Epinat J-C & Gilmore TD. 1999. In vitro-translated diphtheria toxin A chain inhibits translation in wheat germ extracts: analysis of biologically active, caspase-3-resistant diphtheria toxin mutants. Biochimica et Biophysica Acta 1472: 34-41. (Abstract Link)

49.Gilmore TD, J-C Epinat & M Barkett. 1999. Misregulation of a signal transduction pathway: role of Rel/NF-kB transcription factors in oncogenesis. In, DNA Alterations in Cancer: Genetic and Epigenetic Changes (ed. M Ehrlich), BioTechniques Books, Eaton Publishing, Natick, MA, USA. pp 121-136.

50. Koedood Zhao M, Y Wang, K Murphy, J Yi, MC Beckerle & TD Gilmore. 1999. LIM domain-containing protein Trip6 can act as a co-activator for the v-Rel transcription factor. Gene Expression 8: 207-217. (Abstract Link)

51. Gilmore TD. 1999. The Rel/NF-kB signal transduction pathway: introduction. Oncogene 18: 6842-6844. (Abstract Link)

52. Epinat J-C & TD Gilmore. 1999. A variety of agents can act at multiple levels to inhibit the Rel/NF-kB signal transduction pathway. Oncogene 18: 6896-6909. (Abstract Link)

53. Barkett M & TD Gilmore. 1999.  Control of apoptosis by Rel/NF-kB  transcription factors. Oncogene 18: 6910-6924. (Abstract Link)

54. Gilmore TD. 1999. Multiple mutations contribute to the oncogenicity of  the retroviral oncoprotein v-Rel. Oncogene 18: 6925-6937. (Abstract Link)

55. Epinat J-C, D Kazandjian, DD Harkness, S Petros, J Dave, DW White & TD Gilmore. 2000. Mutant Envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein. Oncogene 19: 599-607. (Abstract Link) (Data-link)

56. Epinat J-C, EL Dvorin & TD Gilmore. 2000. Envelope-dependent       transactivation by the retroviral oncoprotein v-Rel is required for efficient  transformation of chicken spleen cells. Oncogene 19: 3131-3137.  (Abstract Link) (Data-link 1)

57. Barkett M, JE Dooher, L Lemonnier, L Simmons, JN Scarpati, Y Wang & TD Gilmore. 2001. Three mutations in the retroviral oncoprotein v-Rel render it resistant to cleavage by caspase-3. Biochimica et Biophysica Acta 1526: 25-36. (Abstract Link) (Data-link 2)

58. Wang Y & TD Gilmore. 2001. LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains. Biochimica et Biophysica Acta 1538: 260-272. (Abstract Link)

59. Piffat KA,  R Hrdlickova,  J Nehyba, T Ikeda, A Liss, S Huang, S Sif, TD Gilmore & HR Bose Jr. 2001. The chicken RelB transcription factor has transactivation sequences and a tissue-specific expression pattern that are distinct from mammalian RelB. Molecular Cell Biology Research Communications 4: 266-275. (Abstract Link) (Data-link 3)

60. Gilmore TD, C Cormier, J Jean-Jacques & M-E Gapuzan. 2001. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene 20: 7098-7103. (Abstract Link) (Data-link 4)

61.Li C, EA Pace, M-C Liang, E Lobkovsky, TD Gilmore & JA Porco Jr. 2001. Total synthesis of the NF-kB inhibitor (-)-cycloepoxydon: utilization of tartrate-mediated nucleophilic epoxidation. Journal of the American Chemical Society 123: 11308-11309.  (Abstract Link)

62.Gilmore TD, M-E Gapuzan, D Kalaitzidis & D Starczynoski. 2002. Rel/NF-kB/IkB signal transduction in the generation and treatment of human cancer. Cancer Letters 181 :1-9. (Abstract Link)

63. Kalaitzidis D & TD Gilmore. 2002. Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. Genes, Chromosomes & Cancer 34: 129-135. (Abstract Link)

64.Gapuzan M-E, P Yufit & TD Gilmore. 2002. Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-kB have a malignantly transformed phenotype. Oncogene 24: 2484-2492. (Abstract Link) (Image Link)

65. Li C, S Bardhan, EA Pace, M-C Liang, TD Gilmore & JA Porco Jr. 2002. The angiogenesis inhibitor epoxyquinol A: total synthesis and inhibition of transcription factor NF-kB. Organic Letters 4: 3267-3270. (Abstract Link)

66. Kalaitzidis D, RE Davis, A Rosenwald, LM Staudt & TD Gilmore. 2002. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kB signal transduction pathway. Oncogene 21: 8759-8768. (Abstract Link)

67. Gilmore TD. 2003. Rel/NF-kB/IkB signal transduction and cancer.  In, Signal Transduction in Cancer (ed. DA Frank), pp 241-265. (Abstract Link)

68. Wang Y & TD Gilmore. 2003. Zyxin and paxillin proteins: focal adhesion plaque LIM domain proteins go nuclear. Biochimica et Biophysica Acta 1593: 115-120. (Abstract Link) (Data-link 5 — Link to full Table 1)

69.  Gilmore TD & G Mosialos. 2003. Viruses as intruders in the Rel/NF-kB signaling pathway.  In, Nuclear Factor-kB: Regulation and Role in Disease (ed. R Beyaert), Kluwer Academic Publishers, The Netherlands, pp 91-115.

70. Liang M-C, S Bardhan, C Li, EA Pace, JA Porco Jr & TD Gilmore. 2003.  Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of Nuclear Factor kB by inhibiting Inhibitor of kB kinase. Molecular Pharmacology 64: 123-131. (Abstract Link)

71. Gapuzan M-ER, GA Pitoc & TD Gilmore. 2003. Mutations within a conserved protein kinase A recognition sequence confer temperature-sensitive and partially defective activities onto mouse c-Rel. Biochemical and Biophysical Research Communications 307: 92-99. (Abstract Link)

72. Starczynowski D, JG Reynolds & TD Gilmore. 2003. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells. Oncogene 22: 6928-6936. (Abstract Link) (Data-link 6)

73.  Gilmore TD, J Jean-Jacques, R Richards, C Cormier, J Kim & D Kalaitzidis. 2003. Stable expression of the avian retroviral oncoprotein v-Rel in avian, mouse, and dog cell lines. Virology 316: 9-16. (Abstract Link)

74. Gilmore TD, D Kalaitzidis, M-C Liang & DT Starczynowski. 2004. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene 23: 2275-2286. (Abstract Link)

75. Kalaitzidis D, J Ok, L Sulak II, D Starczynowski & TD Gilmore. 2004. Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells. Oncogene 23: 7580-7587. (Abstract Link) (Data Link 7)

76. Kalaitzidis D & TD Gilmore. 2005. Transcription factor cross-talk: Estrogen receptor and NF-kB. Trends in Endocrinology and Metabolism 16: 46-52. (Abstract Link) (featured cover photo)

77. Gapuzan M-ER, O Schmah, AD Pollock, A Hoffmann & TD Gilmore. 2005. Immortalized embryonic fibroblasts from NF-kB RelA knockout mice show phenotypic heterogeneity and maintain sensitivity to tumor necrosis factor alpha after transformation by v-Ras. Oncogene 24: 6574-6583. (Abstract Link)

78. Starczynowski DT, JG Reynolds & TD Gilmore. 2005. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL can enhance its in vitro transforming ability. Oncogene 24: 7355-7368. (Abstract Link) (Data Link 8)

79. Liang M-C, S Bardhan, EA Pace, D Rosman, JA Beutler, JA Porco Jr & TD Gilmore. 2006. Inhibition of transcription factor NF-kB signaling proteins IKKb and p65 through specific cysteine residues by epoxyquinone A monomer:  correlation with its anti-cancer cell growth activity. Biochemical Pharmacology 71: 634-645. (Abstract Link)

80. Liang M-C, S Bardhan, JA Porco Jr & TD Gilmore. 2006. The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in an IkBa-deficient diffuse large B-cell lymphoma cell line. Cancer Letters 241: 69-78. (Abstract Link)

81. Perkins ND & TD Gilmore. 2006. Good cop, bad cop: the different faces of NF-kB. Cell Death & Differentiation 13: 759-772. (Abstract Link)

82. Gilmore TD. 2006. Introduction to NF-kB: players, pathways, perspectives. Oncogene 25: 6680-6684. (Abstract Link)

83. Courtois G & TD Gilmore. 2006. Mutations in the NF-kB signaling pathway: implications for human disease. Oncogene 25: 6831-6843. (Abstract Link)

84. Gilmore TD & M Herscovitch. 2006. Inhibitors of NF-kB signaling: 785 and counting. Oncogene 25: 6887-6899. (Abstract Link)

85. Sullivan JC, D Kalaitzidis, TD Gilmore & JR Finnerty. 2007. Rel homology domain-containing transcription factors in the cnidarian Nematostella vectensis. Development Genes and Evolution 217: 63-72. (Abstract Link)

86. Starczynowski DT, H Trautmann, C Pott, L Harder, N Arnold, JA Africa, JR Leeman, R Siebert & TD Gilmore. 2007. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL’s in vitro transforming activity. Oncogene 26: 2685-2694. (Abstract Link) (Data Link 9)

87. Gilmore TD. 2007. Multiple myeloma: lusting for NF-kB. Cancer Cell  12: 95-97. (Abstract Link)

88. Herscovitch M, W Comb, T Ennis, K Coleman, S Yong, B Armstead, D Kalaitzidis, S Chandani & TD Gilmore. 2008. Intermolecular disulfide bond formation in the NEMO dimer requires Cys54 and Cys347. Biochemical and Biophysical Research Communications 367: 103-108. (Abstract Link) (Data Link 10)

89. Leeman JR, MA Weniger, TF Barth & TD Gilmore. 2008. Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL. Oncogene 27: 6770-6781 (Abstract Link) (Data Link 11)

90. Leeman JR & TD Gilmore. 2008. Alternative splicing in the NF-kB signaling pathway. Gene 423: 97-107. (Abstract Link)

91. Garbati MR & TD Gilmore. 2008. Ser484 and Ser494 in REL are the major sites of IKK phosphorylation in vitro: evidence that IKK does not directly enhance GAL4-REL transactivation. Gene Expression 14: 195-205. (Abstract Link) (Data Link 12)

92. Gilmore TD, ND Perkins & G Franzoso. 2009. Getting away from it all in Capri:  The 2008 EMBO Workshop on NF-kB. Cell Death & Differentiation 16: 651-654. (Abstract Link)

93. Chin M*, M Herscovitch*, N Zhang, DJ Waxman & TD Gilmore. 2009. Overexpression of an activated version of the REL oncoprotein enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile. Oncogene 28: 2100-2111. *co-first authors (Abstract Link)

94. Sullivan JD, FS Wolenski, AM Reitzel, CE French, N Traylor-Knowles, TD Gilmore & JR Finnerty. 2009. Two alleles of NF-kB in the sea anemone Nematostella vectensis are widely dispersed in nature and encode proteins with distinct activities. PLoS ONE 4: e7311. doi:10.137/journal.pone.0007311 (Paper Link) (Abstract Link)

95. Garbati MR, G Alco & TD Gilmore. 2010. Histone acetyltransferase p300  is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. Cancer Letters 291: 237-245. (Abstract Link) (Data Link 13)

96. Gilmore TD, RC Thompson & AC Faber. 2010. Cyclins D3 and E go hand in hand with Cdk4/6 in diffuse large B-cell lymphoma. Cell Cycle 9: 448-449. (Abstract Link)

97. Thompson RC*, M Herscovitch*, I Zhao, TJ Ford & TD Gilmore. 2011. NF-kB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. Journal of Biological Chemistry 286: 1675-1681.  (Abstract Link) *co-first authors

98. Garbati M, RC Thompson, L Haery & TD Gilmore. 2011. A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity. Cancer Letters 302: 76-83. (Abstract Link) (Data Link 14).  Published Erratum, in Cancer Letters (2012) 315: 96.

99. Wolenski F, MR Garbati, TJ Lubinski, N Traylor-Knowles, DJ Stefanik, E Dresselhaus, H Goucher, JR Finnerty & TD Gilmore. 2011. Characterization of the core elements of the NF-kB signaling pathway of the sea anemone Nematostella vectensis. Molecular and Cellular Biology 31: 1076-1087.  (Abstract Link) (featured cover photo)

100. Gilmore TD & MR Garbati. 2011. Inhibition of NF-kB signaling as a strategy in disease therapy. Current Topics in Microbiology and Immunology 349:  245-263. (Abstract Link)

101. Gilmore TD & S Gerondakis. 2011. The c-Rel transcription factor in development and disease. Genes & Cancer 7: 695-711 (Abstract Link)

102. Wolenski FS, S Chandani, DJ Stefanik, N Jiang, E Chu, JR Finnerty & TD Gilmore. 2011. Two polymorphic residues account for the differences in DNA binding and transcriptional activation by NF-kB proteins encoded by naturally occurring alleles in Nematostella vectensis. Journal of Molecular Evolution 73: 325-336. (Abstract Link)

103. Yeo AT, JA Porco Jr & TD Gilmore. 2012. Bcl-X_L, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis. Cancer Letters 318: 53-60.  (Abstract Link)

104. Gilmore TD & FS Wolenski. 2011. Evolution of NF-kB: where did it come from and why? Immunological Reviews, in press. (Abstract Link)

105. Berman KJ, Q Hodges, TD Gilmore, V Jamadar-Shroff & SE Suter. 2011. Stable expression of  Rel oncoproteins in canine lymphoid cells. BMC Cancer, in review.

Published Letters to Editor

1. Gilmore TD. 1997. Don’t overlook oncoprotein v-Rel. Journal of NIH Research 9: 14-16.

2. White DW & TD Gilmore. 1997. Transcription factors, oncogenes, and apoptosis. Science (reviewed letter) 276: 185. (Abstract Link)

3. Gilmore TD, DT Starczynowski & D Kalaitzidis. 2004. RELevant gene amplification in B-cell lymphomas? Blood (reviewed letter) 103: 3243. (Abstract Link)

Encyclopedia Entries

1. Gilmore TD. 2001. Rel. In, Encyclopedia of Molecular Medicine. John Wiley & Sons, New York, NY. Volume 3, pp 2752-2754.

2. Gilmore TD. 2001. Rel. In, Encyclopedic Reference of Cancer (M Schwab, editor). Springer-Verlag Publishers, Heidelberg, Germany. pp 761-764.

3. Gilmore TD. 2004 (updated 2010). Nuclear Factor kappaB. In, Encyclopedia of Biological Chemistry (WJ Lennarz & MD Lane, editors). Elsevier, Oxford, UK. Volume 3, pp 96-99.

4. Gilmore TD & YT Ip. 2009. Signal transduction pathways in development and immunity:  NFkB/Rel pathways. (Version 3.0). In, Encyclopedia of Life Sciences, John Wiley & Sons, Ltd. Chichester, UK. http://www.els.net/ [Doi 10.1002/9780470016902.a0002332.pub3]  

5. Gilmore TD. 2008. Rel. In, Encyclopedia of Cancer, 2nd Edition (M Schwab, editor). Springer-Verlag Publishers, Heidelberg, Germany.

6. Gilmore TD. 2011. Rel. In, Encyclopedia of Cancer, 3rd Edition (M Schwab, editor). Springer-Verlag Publishers, Heidelberg, Germany. In press

7. Gilmore TD. 2012. Rel oncogene. In, Brenner’s Online Encyclopedia of Genetics, 2nd Edition (S Malloy, K Hughes, editors). Elsevier, Oxford, UK.  In press